Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis

This study is testing a combination of two immunotherapy drugs — tremelimumab and durvalumab — in patients with advanced liver cancer (hepatocellular carcinoma, or HCC) who also have moderately impaired liver function due to cirrhosis (Child-Pugh B class). Most liver cancer trials exclude these patients, so this study aims to find treatments that work for this group. **You may be eligible if...** - You have confirmed liver cancer (HCC), either at an advanced stage or not suitable for local treatments - You have moderate cirrhosis (Child-Pugh B7 or B8) - You have not had prior systemic (whole-body) therapy for liver cancer - If you have hepatitis B, you must be on effective antiviral therapy with a low viral load - Your blood counts, liver function, and kidney function meet the required thresholds **You may NOT be eligible if...** - Your liver cancer could potentially be cured with surgery or ablation - You have had an episode of uncontrolled liver-related brain confusion (encephalopathy) in the past 6 months - You have active alcohol or substance abuse - You have active autoimmune disease (other than manageable conditions like thyroid disease or vitiligo) - You have had an organ transplant - You are pregnant or breastfeeding - You have known allergy to either study drug Talk to your doctor to see if this trial is right for you.